



PATENT
Customer No. 22,852
Attorney Docket No. 08201.0027-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
BROWNING et al.) Group Art Unit: 1647
Application No.: 10/077,438) Examiner: B. Bunner
Filed: February 15, 2002)
For: BAFF RECEPTOR (BCMA), AN) Confirmation No.: 3507
IMMUNOREGULATORY AGENT)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

The references listed on the attached Form SB/08 were submitted in a prior Information Disclosure Statement dated July 12, 2004. Pursuant to 1.98(d), copies of the references were not enclosed because they were submitted in the prior application, 10/077,137, filing date February 15, 2002, upon which applicants rely for the benefits provided in 35 U.S.C. § 120. Upon the request of the Examiner, applicants hereby enclose copies of the references for the Examiner's review.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 8, 2005

By:


Leslie A. McDonell
Reg. No. 34,872



IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/077,438
				Filing Date	February 15, 2002
				First Named Inventor	Jeffrey Browning
				Art Unit	1647
				Examiner Name	B. Bunner
Sheet	1	of	1	Attorney Docket Number	08201.0027-01000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation ⁶
		Hahne et al., "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," <i>J. Exp. Med.</i> 188:1185-1190 (1998)			
		Kashii, Y. et al., "Constitutive Expression and Role of the TNF Family Ligands in Apoptotic Killing of Tumor Cells By Human NK Cells," <i>J. Immunol.</i> 163:5358-66 (1999)			
		von Bülow & Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily," <i>Science</i> 278:138-141 (1997)			
		Ward, P. and Mulligan, M. "Blocking of Adhesion Molecules <i>in vivo</i> As Anti-Inflammatory Therapy," <i>Ther. Immunol.</i> 1:165-71 (1994)			
		Ware, C., "APRIL and BAFF Connect Autoimmunity and Cancer," <i>J. Exp. Med.</i> 192:F35-F37 (2000)			
		Xia et al., "TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> 192:137-143 (2000)			
		Yu et al., "APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity," <i>Nature Immunol.</i> 1:252-256 (2000)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.